Dr. Lal PathLabs Board Approves FY26 Results, ₹4 Dividend, Acquisitions

Dr. Lal PathLabs' Board of Directors met on April 30, 2026, to approve several key decisions. The board approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. A final dividend of INR 4/- per equity share (40% on face value of INR 10/-) was recommended for FY26, with a record date of June 26, 2026. The company also announced the acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited (SDCPL), making it a wholly-owned subsidiary. Furthermore, a new wholly-owned subsidiary, Dr. Lal PathLabs FZCO, will be incorporated in Dubai, UAE. The board re-appointed Dr. Arvind Lal as Executive Chairman and Mr. Rajit Mehta as Non-Executive Independent Director. Dr. Reena Nakra and Dr. Saloni Khera were designated as Senior Management Personnel. M/s Ernst & Young LLP and M/s A.G. Agarwal & Associates were re-appointed as Internal and Cost Auditors, respectively, for FY2026-27. Additionally, 82,750 equity shares were allotted under the Employee Stock Option Plan 2022.